

# Relationships Between Serum Unsaturated Fatty Acids and Coronary Risk Factors

## Negative Relations Between Nervonic Acid and Obesity-Related Risk Factors

Eiji ODA,<sup>1</sup> MD, Katsuharu HATADA,<sup>2</sup> MD, Jun KIMURA,<sup>2</sup> MD, Yoshifusa AIZAWA,<sup>2</sup> MD, Punniyakoti Veeraveedu THANIKACHALAM,<sup>3</sup> PhD, and Kenichi WATANABE,<sup>3</sup> MD

### SUMMARY

Relative increases in unsaturated fatty acids (USFA) in the diet are considered to exert beneficial effects on coronary risk factors (CRF). However, detailed analysis of the relationships between serum USFA and CRF are scanty and there is no report of the relationship between nervonic acid (NA) and CRF. The objective of the present study was to analyze the relationships between serum USFA and CRF.

Body height and weight, blood pressure, fasting serum total cholesterol (TC), triacylglycerol (TG), HDL cholesterol (HDLc), fasting blood sugar (FBS), total fatty acid composition, leptin, and high-sensitivity C-reactive protein (CRP) were measured in 31 men (age, 41-78 years) and 11 women (age, 54-77 years). The relationships between serum USFA, and body mass index (BMI), leptin, systolic blood pressure (SBP), diastolic blood pressure (DBP), TC, TG, HDLc, FBS, and CRP were analyzed using multiple regression analysis. The final results were summarized using coronary risk factor scores (CRFS) in order to assess the correlations between USFA with CRF.

Oleic acid (OA), linoleic acid (LA), and eicosapentaenoic acid (EPA) were positively related to coronary risk factors (total CRFS = 2, 3, and 4, respectively), while nervonic acid (NA) exerted negative effects on these risk factors (total CRFS = -6). It is concluded NA may have preventive effects on obesity-related metabolic disorders. (*Int Heart J* 2005; 46: 975-985)

**Key words:** Leptin, Metabolic syndrome, Obesity, Diabetes mellitus

**O**BESITY, hypertension, diabetes mellitus (DM), dyslipidemia, and insulin resistance (metabolic syndrome) are increasing in frequency and becoming major causes of cardiovascular diseases.<sup>1)</sup> The excess intake of energy and a sedentary lifestyle are major causes of these morbid conditions. Excess saturated fatty acids

---

From the <sup>1</sup> Department of Internal Medicine, Niigata Prefectural Yoshida Hospital, <sup>2</sup> Division of Cardiology, Hematology, Endocrinology and Metabolism, Niigata University Graduate School of Medical and Dental Science, <sup>3</sup> Department of Clinical Pharmacology, Niigata College of Pharmacy, Niigata, Japan.

Address for correspondence: Eiji Oda, MD, Department of Internal Medicine, Niigata Prefectural Yoshida Hospital, Daibochou 32-14, Yoshida, Nishikanbara, Niigata 959-0242, Japan.

Received for publication May 10, 2005.

Revised and accepted August 1, 2005.

(SF) and a relative deficiency in unsaturated fatty acids (USFA), especially n-3 polyunsaturated fatty acids (PUFA), have been identified as contributing factors.<sup>2)</sup> However, detailed studies on the relationships between serum USFA and coronary risk factors (CRF) are limited. In this report, we analyzed the relationships between serum USFA, and body mass index (BMI),<sup>3)</sup> leptin,<sup>4)</sup> systolic blood pressure (SBP), diastolic blood pressure (DBP),<sup>5)</sup> total cholesterol (TC), triacylglycerol (TG),<sup>6)</sup> HDL cholesterol (HDLc), fasting blood sugar (FBS),<sup>7)</sup> and high-sensitivity C-reactive protein (CRP)<sup>8)</sup> (collectively defined as CRF in this report).

## METHODS

**Subjects:** Thirty-one males (age, 41-78 years) and 11 females (age, 54-77 years) without an existing or history of overt atherosclerotic cardiovascular disease, or overt diabetes mellitus who were enrolled in the control group in a previous case-control study on n-3 PUFA as a negative risk factor for myocardial infarction,<sup>9)</sup> were the subjects in the present study. Written informed consent was obtained from all subjects and the ethics committee of all hospitals approved the study.

**Measurements:** Fasting blood samples were obtained from all subjects. Body height and weight, blood pressure, fasting blood sugar (FBS), total cholesterol (TC), triacylglycerol (TG), and HDL cholesterol (HDLc) were measured at each of the participating hospitals (see Appendix). Serum total fatty acid composition, CRP, and leptin were measured at a commercial laboratory center in Japan (SRL Inc.). Serum total fatty acid composition was measured using Omegawax 250 (SUPELCO, gas-chromatography), and serum leptin was measured using a Human Leptin RIA Kit (LINCO Research Inc.).

**Statistical analysis:** The mean and SD of each variable were calculated separately by gender, and sexual differences were examined with unpaired *t*-tests. *P* values less than 0.05 were considered to be significant. BMI, leptin, SBP, DBP, TC, TG, HDLc, FBS, and CRP were analyzed by multiple regression analysis using the combination of oleic acid (OA, C18:1:n-9), linoleic acid (LA, C18:2:n-6), linolenic acid (LNA, C18:3:n-3), arachidonic acid (AA, C20:4:n-6), eicosa-pentaenoic acid (EPA, C20:5:n-3), and nervonic acid (NA, C24:1:n-9), or the combination of total n-9 monounsaturated fatty acids (MUFA) ( $\Sigma n9$ ), total n-6 polyunsaturated fatty acids (PUFA) ( $\Sigma n6$ ), and total n-3 PUFA ( $\Sigma n3$ ) as independent variables. Other USFA and total saturated fatty acids ( $\Sigma SF$ ) were omitted from the independent variables in order to avoid multicollinearity. Both fatty acid data expressed in  $\mu\text{g/mL}$  and wt% (weight % of individual fatty acid/total fatty acids) were analyzed separately. The former values express the absolute concentrations of fatty acids, while the latter express their relative quantities. *P* values less than 0.05 were considered to be significant. The coronary risk factor score

(CRFS) was defined as follows. Independent variables were given a score, plus one, with each risk factor except for HDLc, when the coefficients were significantly positive, and given a score, minus one, when the coefficients were significantly negative. For HDLc, the score was minus one when the coefficients were significantly positive and plus one when the coefficients were significantly negative. The CRFS for each individual variable was defined as the summation of the scores.

## RESULTS

**Baseline data:** The mean and SD of the coronary risk factors are presented in Table I. There were significant gender differences in leptin and HDLc. The mean and SD of each fatty acid and each fatty acid class are presented in Table II. There were no significant gender differences in any variable.

**Multiple regression of CRF using USFA and fatty acid class ( $\mu\text{g/mL}$ ) separately as independent variables:** The results of multiple regression analysis of CRF using USFA and fatty acid class in  $\mu\text{g/mL}$  separately as independent variables are shown in Table III. OA was significantly positively correlated to TG and significantly negatively correlated to HDLc. LA was significantly positively correlated to leptin and TC, and EPA was significantly positively correlated to BMI, leptin, TC, and FBS. NA was significantly negatively correlated to leptin. With respect to fatty acid class,  $\Sigma\text{n9}$  was significantly positively correlated to TG and significantly negatively correlated to TC and HDLc, while  $\Sigma\text{n6}$  was significantly negatively correlated to TG and significantly positively correlated to leptin, TC, and HDLc.  $\Sigma\text{n3}$  was significantly positively correlated to SBP and TC.

**Table I.** Basal Data of Multiple Coronary Risk Factors

	Male <sup>1</sup>		Female <sup>2</sup>		<i>p</i> <sup>3</sup>
	Mean	SD	Mean	SD	
Age (years)	57.4	10.7	61.4	7.1	NS
BMI (kg/m <sup>2</sup> )	24.8	3.8	23.6	3.7	NS
leptin (ng/mL)	5.3	2.5	7.6	4.7	< 0.05
SBP (mmHg)	127	20	131	25	NS
DBP (mmHg)	73	13	76	17	NS
TG (mg/dL)	122	76	118	43	NS
TC (mg/dL)	202	29	223	40	NS
HDLc (mg/dL)	57	14	70	17	< 0.05
FBS (mg/dL)	101	13	97	17	NS
CRP (ng/mL)	2265	6836	1107	1560	NS

<sup>1</sup>*n* = 32, <sup>2</sup>*n* = 11, <sup>3</sup>Calculated with unpaired *t*-tests. Values more than 0.05 are presented as NS (not significant).

**Table II.** Basal Data of Fatty Acid Composition

$\mu\text{g/mL}$	Male <sup>1</sup>		Female <sup>2</sup>		$P^3$	wt%	Male <sup>1</sup>		Female <sup>2</sup>		$P^3$
	mean	SD	mean	SD			mean	SD	mean	SD	
C12:0	1.4677	1.336	2.282	1.99	NS	C12:0	0.042	0.029	0.062	0.046	NS
C14:0	28.497	14.59	35.03	17.4	NS	C14:0	0.832	0.247	0.945	0.354	NS
C16:0	770.65	244.6	847.2	212.7	NS	C16:0	23.2	1.61	23.24	2.238	NS
C16:1:n7	69.294	37.2	80.41	35.57	NS	C16:1:n7	2.024	0.651	2.188	0.745	NS
C18:0	233.43	53.3	264.4	50.55	NS	C18:0	7.165	0.54	7.32	0.462	NS
C18:1:n9	658.45	263.9	668	139	NS	C18:1:n9	19.47	2.574	18.49	1.847	NS
C18:2:n6	896.08	225.1	988.3	206.7	NS	C18:2:n6	27.5	3.739	27.44	3.944	NS
C18:3:n6	10.7	7.253	13.2	5.647	NS	C18:3:n6	0.311	0.161	0.356	0.114	NS
C18:3:n3	29.016	15.03	32.74	12.41	NS	C18:3:n3	0.863	0.242	0.887	0.221	NS
C20:0	8.0065	1.883	8.391	1.466	NS	C20:0	0.248	0.044	0.235	0.038	NS
C20:1:n9	6.0129	2.535	6.036	1.556	NS	C20:1:n9	0.181	0.044	0.167	0.029	NS
C20:2:n6	6.3194	1.708	6.718	2.256	NS	C20:2:n6	0.194	0.025	0.181	0.035	NS
C20:3:n6	33.048	13.5	36.49	14.11	NS	C20:3:n6	0.997	0.282	0.991	0.281	NS
C20:4:n6	161.93	46.18	191.4	41.69	NS	C20:4:n6	5.005	1.042	5.356	0.971	NS
C20:5:n3	109.23	63.61	127.1	55.8	NS	C20:5:n3	3.417	1.92	3.477	1.367	NS
C22:0	19.265	5.106	21.03	4.484	NS	C22:0	0.595	0.123	0.586	0.097	NS
C22:1:n9	2.4839	1.139	2.182	0.84	NS	C22:1:n9	0.08	0.042	0.061	0.028	NS
C22:4:n6	3.6935	1.397	4.1	1.081	NS	C22:4:n6	0.112	0.026	0.114	0.022	NS
C22:5:n3	26.194	10.37	27.7	8.322	NS	C22:5:n3	0.794	0.221	0.761	0.134	NS
C22:6:n3	17.49	4.012	17.77	3.329	NS	C22:6:n3	0.546	0.103	0.497	0.073	NS
C24:0	165.33	54.36	195.4	46.63	NS	C24:0	5.129	1.507	5.417	0.799	NS
C24:1:n9	38.787	7.044	41.1	5.068	NS	C24:1:n9	1.24	0.316	1.175	0.253	NS
$\Sigma\text{SF}^4$	1078.8	314.6	1196	279.6	NS	$\Sigma\text{SF}^4$	32.63	1.477	32.89	2.52	NS
$\Sigma\text{n}9^5$	707.61	268.1	719.2	141.1	NS	$\Sigma\text{n}9^5$	20.71	2.382	19.67	1.869	NS
$\Sigma\text{n}6^6$	1111.8	271.3	1240	242.1	NS	$\Sigma\text{n}6^6$	34.12	4.214	34.43	4.09	NS
$\Sigma\text{n}3^7$	329.76	131	382.8	108.4	NS	$\Sigma\text{n}3^7$	10.2	3.596	10.54	2.02	NS

<sup>1</sup> $n = 31$ , <sup>2</sup> $n = 11$ <sup>3</sup>Calculated with unpaired *t*-tests. Values more than 0.05 are presented as NS (not significant).<sup>4</sup>total saturated fatty acids, <sup>5</sup>total n-9 monounsaturated fatty acids,<sup>6</sup>total n-6 polyunsaturated fatty acids, <sup>7</sup>total n-3 polyunsaturated fatty acids.

**Multiple regression analysis of CRF using USFA and fatty acid class (wt%) separately as independent variables:** The results of multiple regression analysis of CRF using USFA and fatty acid class (wt%) as independent variables are shown in Table IV. OA was significantly negatively correlated to leptin and significantly positively correlated to TG. LA was significantly positively correlated to TC, and NA was significantly negatively correlated to BMI, leptin, TG, TC, and FBS. Significant negative correlations were found between leptin and all three unsaturated fatty acid classes, and between HDLc and  $\Sigma\text{n}9$ . No significant correlation was found between LNA, AA, EPA, and CRF.

**Total CRFS:** Among individual USFA, OA, LA, and EPA had positive total CRFS (2, 3, and 4, respectively), while NA had a negative total CRFS (−6). As

**Table III.** Multiple Regressions for Risk Factors Using USFA (unsaturated fatty acids) or Fatty Acid Classes ( $\mu\text{g/mL}$ ) as Independent Variables<sup>1</sup>

$\mu\text{g/mL}$	BMI		Leptin		SBP		DBP		TG		TC		HDLc		FBS		CRP		CRFS <sup>2</sup>
	$\beta^3$	$P^4$	$\beta^3$	$P^4$	$\beta^3$	$P^4$	$\beta^3$	$P^4$	$\beta^3$	$P^4$	$\beta^3$	$P^4$	$\beta^3$	$P^4$	$\beta^3$	$P^4$	$\beta^3$	$P^4$	
intercept	23.71	< 10 <sup>-6</sup>	4.6652	NS	99.66	< 10 <sup>-4</sup>	45.15	< 0.01	40.96	NS	68.14	< 0.01	45.42	< 0.01	81.51	< 10 <sup>-7</sup>	4476	NS	
OA <sup>5</sup>	0.005	NS	-0.001	NS	0.002	NS	0.011	NS	0.273	< 10 <sup>-8</sup>	-0.01	NS	-0.04	< 0.05	0.028	NS	-2.66	NS	2
LA <sup>6</sup>	0.008	NS	0.0098	< 0.05	0.023	NS	0.026	NS	-0.07	NS	0.143	< 10 <sup>-5</sup>	0.034	NS	0.027	NS	-4.52	NS	2
LNA <sup>7</sup>	-0.08	NS	-0.038	NS	-0.37	NS	-0.12	NS	0.94	NS	-0.78	NS	-0.23	NS	-0.11	NS	-31.1	NS	0
AA <sup>8</sup>	-0.02	NS	0.0065	NS	-0.04	NS	-0.08	NS	-0.13	NS	0.027	NS	0.135	NS	-0.08	NS	10.95	NS	0
EPA <sup>9</sup>	0.024	< 0.05	0.0189	< 0.05	0.117	NS	0.008	NS	0.106	NS	0.177	< 0.01	0.07	NS	0.074	< 0.05	5.736	NS	4
NA <sup>10</sup>	-0.16	NS	-0.234	< 0.01	0.281	NS	0.319	NS	-1.44	NS	0.398	NS	-0.31	NS	-0.39	NS	46.37	NS	-1
intercept	19.53	< 10 <sup>-7</sup>	-1.578	NS	106	< 10 <sup>-7</sup>	51.15	< 10 <sup>-4</sup>	-19.7	NS	81.86	< 10 <sup>-5</sup>	41.77	< 10 <sup>-3</sup>	68.65	< 10 <sup>-8</sup>	6153	NS	
$\Sigma\text{n}9^{11}$	0.002	NS	-0.002	NS	-0.02	NS	0.002	NS	0.31	< 10 <sup>-9</sup>	-0.06	< 0.01	-0.06	< 0.01	0.023	NS	-4.89	NS	1
$\Sigma\text{n}6^{12}$	0.001	NS	0.006	< 0.05	0.016	NS	0.017	NS	-0.09	< 0.05	0.128	< 10 <sup>-6</sup>	0.041	< 0.01	0.004	NS	-1.46	NS	0
$\Sigma\text{n}3^{13}$	0.006	NS	0.0065	NS	0.058	< 0.05	0.006	NS	0.067	NS	0.072	< 0.05	0.032	NS	0.028	NS	2.777	NS	2

<sup>1</sup>n = 42. <sup>2</sup>Independent variables were given a score, plus one, with each risk factor except for HDLc when the coefficient was significantly positive, and given a score, minus one, when the coefficient was significantly negative. As for HDLc the score was minus one when the coefficient was significantly positive and plus one when the coefficient was significantly negative. CRFS for each individual variable was defined as the summation of the scores. <sup>3</sup>partial regression coefficient. <sup>4</sup>Values more than 0.05 are presented as NS (not significant). <sup>5</sup>oleic acid, <sup>6</sup>linoleic acid, <sup>7</sup>linolenic acid, <sup>8</sup>arachidonic acid, <sup>9</sup>eicosapentaenoic acid, <sup>10</sup>nervonic acid, <sup>11</sup>total n-9 monounsaturated fatty acids, <sup>12</sup>total n-6 polyunsaturated fatty acids, <sup>13</sup>total n-3 polyunsaturated fatty acids.

**Table IV.** Multiple Regressions for Risk Factors Using USFA or Fatty Acid Classes (wt%) as Independent Variables<sup>1</sup>

wt%	BMI		Leptin		SBP		DBP		TG		TC		HDLc		FBS		CRP		CRFS <sup>2</sup>
	$\beta^3$	$P^4$	$\beta^3$	$P^4$	$\beta^3$	$P^4$	$\beta^3$	$P^4$	$\beta^3$	$P^4$	$\beta^3$	$P^4$	$\beta^3$	$P^4$	$\beta^3$	$P^4$	$\beta^3$	$P^4$	
intercept	39.62	< 0.05	39.683	< 0.01	240.7	< 0.05	94.58	< 0.05	33.42	NS	55.11	NS	131.17	NS	29.42	NS	39789	NS	
OA <sup>5</sup>	-0.12	NS	-0.79	< 0.05	-2.36	NS	0.237	NS	11.42	< 0.05	3.469	NS	-3.32	NS	2.675	NS	-1102	NS	0
LA <sup>6</sup>	0.059	NS	-0.148	NS	-0.9	NS	0.528	NS	-2.07	NS	5.525	< 0.05	0.0468	NS	1.487	NS	-555	NS	1
LNA <sup>7</sup>	-2.59	NS	-0.206	NS	-16.5	NS	-7.88	NS	61.13	NS	-21.6	NS	-9.151	NS	2.877	NS	-4221	NS	0
AA <sup>8</sup>	-1.21	NS	-0.583	NS	-3.65	NS	-3.79	NS	-4.58	NS	0.209	NS	3.1171	NS	-2.17	NS	110.5	NS	0
EPA <sup>9</sup>	0.302	NS	-0.563	NS	0.69	NS	-0.15	NS	3.846	NS	8.998	NS	0.1979	NS	3.959	NS	-484	NS	0
NA <sup>10</sup>	-5.73	< 0.05	-7.723	< 10 <sup>-4</sup>	-9.74	NS	-10.6	NS	-96.6	< 10 <sup>-3</sup>	-64.6	< 0.01	-14.09	NS	-22.2	< 0.01	2752	NS	-5
intercept	55.05	< 0.05	56.886	< 0.01	221.5	NS	106.4	NS	199.2	NS	103.9	NS	153.93	NS	32.66	NS	38795	NS	
$\Sigma\text{n}9^{11}$	-0.44	NS	-0.992	< 0.05	-2.28	NS	-0.05	NS	10.75	NS	1.81	NS	-3.848	< 0.05	2.592	NS	-1167	NS	0
$\Sigma\text{n}6^{12}$	-0.5	NS	-0.642	< 0.01	-1.35	NS	-0.62	NS	-7.76	NS	1.762	NS	-0.221	NS	0.083	NS	-315	NS	-1
$\Sigma\text{n}3^{13}$	-0.44	NS	-0.847	< 0.01	-0.08	NS	-0.99	NS	-3.16	NS	0.643	NS	-0.745	NS	1.081	NS	-215	NS	-1

<sup>1</sup>n = 42. <sup>2</sup>Independent variables were given a score, plus one, with each risk factor except for HDLc when the coefficient was significantly positive, and given a score, minus one, when the coefficient was significantly negative. As for HDLc the score was minus one when the coefficient was significantly positive and plus one when the coefficient was significantly negative. CRFS for each individual variable was defined as the summation of the scores. <sup>3</sup>partial regression coefficient. <sup>4</sup>Values more than 0.05 are presented as NS (not significant). <sup>5</sup>oleic acid, <sup>6</sup>linoleic acid, <sup>7</sup>linolenic acid, <sup>8</sup>arachidonic acid, <sup>9</sup>eicosapentaenoic acid, <sup>10</sup>nervonic acid, <sup>11</sup>total n-9 monounsaturated fatty acids, <sup>12</sup>total n-6 polyunsaturated fatty acids, <sup>13</sup>total n-3 polyunsaturated fatty acids.

for fatty acid classes, n-6 PUFA had a negative total CRFS (-1), while n-9 MUFA and n3 PUFA had positive total scores.<sup>1)</sup>

## DISCUSSION

The relationships between USFA and coronary risk factors are controversial. Kris-Etherton, *et al* concluded that, although not all epidemiologic studies have demonstrated a beneficial association between PUFA and cardiovascular disease, n-6 PUFA have the most potent cholesterol-lowering effects of the individual fatty acid classes in their review.<sup>10)</sup> Bemelmans, *et al* reported in their longitudinal study that increased LNA intakes resulted in lower HDLc and higher TG than did increased LA intakes.<sup>11)</sup> Djousse, *et al* reported in their cross-sectional study that consumption of total LNA was inversely related to TG.<sup>12)</sup> Zhao, *et al* reported in their interventional study that both an LA diet and LNA diet decreased TC, LDL cholesterol, and TG similarly and that an LNA diet decreased CRP and HDLc.<sup>13)</sup> However, these dietary studies are different from studies investigating the associations between serum fatty acid composition with CRF defined above, though there are some correlations between diet and plasma fatty acid composition. Ma, *et al* reported in their cross-sectional dietary intake study<sup>14)</sup> that the Pearson correlations between dietary and plasma fatty acid (expressed as % of total fatty acids) for phospholipid (PL) and cholesterol ester (CE), respectively, were as follows: saturated fatty acids ( $r = 0.15$  and  $0.23$ ), MUFA ( $r = 0.05$  and  $0.01$ ), PUFA ( $r = 0.25$  and  $0.31$ ), LA ( $r = 0.22$  and  $0.28$ ), LNA ( $r = 0.15$  and  $0.21$ ), EPA ( $r = 0.20$  and  $0.23$ ), and DHA ( $r = 0.42$  and  $0.42$ ), ( $n = 3570$ ). Wang, *et al* prospectively investigated the correlations between plasma CE and PL fatty acid composition with the incidence of coronary heart disease (CHD) and reported that in both CE and PL fractions, the proportions (% of total fatty acid) of stearic acid, D  $\gamma$ LNA, and  $\Sigma$ SF were significantly higher while AA and total PUFA were significantly lower among patients with CHD.<sup>15)</sup> LNA in the CE fraction was also significantly positively correlated to CHD and monounsaturated fatty acids were not associated with CHD in their report.<sup>15)</sup>

In the present cross-sectional study, among individual USFA, OA, LA, and EPA were positively correlated to CRF (CRFS = 2, 2, and 4, respectively), while NA was negatively correlated to CRF (CRFS = -1), when expressed as absolute concentrations ( $\mu\text{g/mL}$ ). As for the class of fatty acid, n-6 PUFA had a negative CRFS (= -1), while both n-3 PUFA and n-9 MUFA had a positive CRFS (= 1) (Table III). When expressed as proportions of total fatty acids (wt%), LA was positively correlated to CRF (CRFS = 1), while NA was negatively correlated to CRF (CRFS = -5). With respect to fatty acid class, n-9 MUFA had a neutral CRFS (= 0), while both n-6 PUFA and n-3 PUFA had a negative CRFS (= -1)

(Table IV). Therefore, OA, LA, and EPA had overall positive correlations to CRF (total CRFS = 2, 3, and 4, respectively), while NA had an overall negative correlation to CRF (total CRFS = -6). With respect to fatty acid class, n-6 PUFA had a negative total CRFS (= -1), while both n-3 PUFA and n-9 MUFA had a positive total CRFS (= 1). Relative concentrations (wt%) of USFA may mainly reflect their favorable nature as regulators of metabolism such as ligands for peroxisome proliferator-activated receptors,<sup>16,17)</sup> while their absolute concentrations may mainly reflect their property as fuel rather than information molecules. We must consider both these characteristics in dietary or supplementary strategies. Therefore, we propose total CRFS as a measure for an overall assessment. The overall favorable correlation between n-6 PUFA and CRF may explain the results of Wang, *et al*, who found AA was inversely related to CHD.<sup>15)</sup> Though having a positive CRFS in our study, n-3 PUFA has been shown to reduce the incidence of cardiovascular diseases and sudden death, and consequently has been recommended in the American Heart Association Dietary Guidelines.<sup>18)</sup> Therefore, the beneficial effects of n-3 PUFA or EPA on CHD may be related to factors other than CRF such as ion channels,<sup>19)</sup> plaque stability,<sup>20)</sup> myocardial oxygen consumption,<sup>21)</sup> eicosanoids,<sup>22)</sup> platelet aggregation,<sup>23)</sup> endothelial function,<sup>24)</sup> and Src family kinase inhibition.<sup>25)</sup> From the standpoint of dietary evolution and eicosanoid metabolism, Simopoulos proposed adopting the n-6/n-3 PUFA ratio of 1-2/1, while current estimates in Western cultures suggest an n-6/n-3 PUFA ratio of 10-20/1.<sup>22)</sup> On the other hand, Wijendran, *et al* recommended an n-6/n-3 ratio of 6/1 as an achievable level for most healthy adults in Western cultures.<sup>26)</sup> However, Brady, *et al* reported in their interventional study that the background dietary n-6 PUFA concentration did not modulate the effect of n-3 PUFA supplementation on blood lipids or measures of insulin sensitivity,<sup>27)</sup> and Mozaffarian, *et al* reported in their longitudinal study that n-3 PUFA may reduce coronary heart disease risk, with little apparent influence from background n-6 PUFA intake.<sup>28)</sup> These observations may reflect the beneficial relation of n-6 PUFA with CRF detected in our study. Although n-3 PUFA is established as a protective nutritional substance against sudden death,<sup>29,30)</sup> relationships between n-3 PUFA and nonfatal myocardial infarction are controversial.<sup>31-33)</sup> Guallar, *et al* reported that there was no difference in plasma fish oil levels between patients with myocardial infarction and the control in a prospective nested case-control study (the Physician's Health Study),<sup>31)</sup> while Tavani, *et al* showed in their case-control study that n-3 PUFA was inversely related to nonfatal myocardial infarction.<sup>33)</sup> We reported that n-3 PUFA may be negatively related to nonfatal myocardial infarction and the optimal n-6/n-3 PUFA ratio may be lower than 3/1 in a case-control study<sup>9)</sup> conducted in Japan where the incidence of myocardial infarction is low and the mean ratio of n-6/n-3 PUFA is about 3/1. Siscovick, *et al* suggested

a possible threshold for n-3 PUFA intake (the equivalent of one fatty fish meal a week) for a marked reduction in cardiac sudden death.<sup>34)</sup> We suggest another higher possible threshold for a reduction in nonfatal myocardial infarction, because the protective effects of n-3 PUFA from nonfatal myocardial infarction are obscure in Western cultures where n-3 PUFA intake is very low,<sup>29,31,32)</sup> whereas these effects may be evident in epidemiological studies comparing different (in regard to fish consumption) ethnic groups<sup>35)</sup> and the protective effect was observed at very high levels of n-3 PUFA compared to those in Western cultures in our previous study.<sup>9)</sup>

NA, as well as DHA, is well-known as a major component of brain phospholipids, and has been suggested as a therapeutic supplement for demyelinating diseases by some investigators.<sup>36)</sup> However, it is catabolized in peroxisomes as are other very long chain fatty acids, and this process is defective in some demyelinating diseases, so, the efficacy of dietary NA therapy has been questioned by others.<sup>37)</sup> There are no previous reports concerning the association between NA with CRF or CHD. Our study may be the first report describing negative associations for NA with BMI, leptin, TG, TC, and FBS. Bang, *et al*<sup>35)</sup> pointed out the following two facts in their report. "The polyunsaturated fatty acids were predominantly of the linolenic class (n-3) in Eskimo diets and the linoleic class (n-6) in Danes. Monoenes other than palmitoleic and oleic acids were high in Eskimo diets, but negligible in Danish". Most of the monoenes other than OA and POA in Eskimo diets described by Bang, *et al* were C20:1 and C22:1, which shortens to C18:1:n-9 (OA) or elongates to C24:1:n-9 (NA) *in vivo*.<sup>38)</sup> According to the report by Dyerberg, *et al*<sup>39)</sup> the average plasma fatty acid compositions of MUFA in Greenland Eskimos were OA = 25% > POA(C16:1:n-9) = 9% > NA = 0.88% > C20:1 = 0.05% > other MUFA in cholesterol esters, OA = 35% > POA = 9.47% > C20:1 = 3.35% > NA = 0.15% > C14:1 = 0.04% > C22:1 = 0.01% > other MUFA in triacylglycerols including free fatty acids and OA = 16% > C20:1 = 2.73% > POA = 2.68% > NA = 0.13% > other MUFA in phospholipids. In our data, the average serum total fatty acid composition of MUFA was OA = 20% > POA = 2.2% > NA = 1.3% > EA (C20:1:n-9) = 0.2% > ERA (C22:1:n-9) = 0.07% > other MUFA. In certain species C22:1 depresses body weight gain mainly through an anorectic effect and causes cardiac fibrosis due to lipid accumulation.<sup>40)</sup> However, it is known that adaptation occurs to low doses<sup>35)</sup> or to prolonged exposure to C22:1,<sup>41)</sup> Though possibly toxic in large doses,<sup>40)</sup> certain doses of certain very long chain MUFA, including NA, may not only be nontoxic in humans,<sup>42)</sup> but also lead to prevention from obesity-related metabolic disorders, as the results of the present study suggest, and, together with n-3 PUFA, provide protection against coronary heart disease, as is the case in Eskimo diets.<sup>35)</sup> Dietary intervention studies on the relationship between NA and obesity-related meta-



bolic disorders may be warranted.

**Limitations:** The size of the present study population was rather small and the measurement procedures for some variables were not precisely defined. Therefore, the values could include undue errors. However, these errors might lead to nonsignificant results rather than significant associations. Therefore, the significant results in our present study may be relevant.

### ACKNOWLEDGMENTS

The authors wish to thank all investigators (listed in the appendix) and subjects who participated in this study. The study was partially supported by Mochida Pharmaceutical Company. The authors had no personal or financial conflicts of interest.

### APPENDIX

**Investigators (Hospitals):** Yoshifusa Aizawa, Makoto Kodama, Haruo Hanawa, Kiminori Katoh, Yuichi Nakamura, Katsuharu Hatada (Niigata University Hospital); Kaoru Suzuki, Eiichi Itoh, Yasuhiko Tanabe, Akimitsu Nasuno (Niigata Prefectural Shibata Hospital); Takashi Tsuda, Takefumi Miyajima, Toshio Yamaguchi (Kido Hospital); Hideaki Ohtsuka, Yasushi Miyakita, Takaaki Shiono, Koutarou Higuchi (Niigata Kobari Hospital); Masaaki Okabe, Junji Ishiguro, Masahito Satoh, Hitoshi Kitazawa, Minoru Takahashi, Yoshio Ikeda, Satoru Hirono, Mitsuru Katoh, Shinichi Morita, Takashi Yamamoto (Tachikawa General Hospital); Tsuneo Nagai, Katsuya Ebe, Toshio Fujita, Yukiko Ohno (Nagaoka Red Cross Hospital); Fumiaki Masani, Osamu Ogawa, Hajime Takano (Niigata Prefectural Central Hospital); Kunio Koderu (Niigata Rousai Hospital); Minoru Murata, Kouji Oohira (Mito Saiseikai Hospital); Takanao Aoki, Takaaki Kubo, Ryuuta Imaki, Kazuyuki Ozaki (Takeda General Hospital); Akihiro Abe, Eiji Oda (Niigata Prefectural Yoshida Hospital).

### REFERENCES

1. Haffner S, Taegtmeier H. Epidemic obesity and the metabolic syndrome. *Circulation* 2003; 108: 1541-5. (Review)
2. Wolfram G. Dietary fatty acids and coronary heart disease. *Eur J Med Res* 2003; 20: 321-4. (Review)
3. Jonsson S, Hedblad B, Engstrom G, Nilsson P, Berglund G, Janzon L. Influence of obesity on cardiovascular risk. Twenty-three-year follow-up of 22,025 men from an urban Swedish population. *Int J Obes Relat Metab Disord* 2002; 26: 1046-53.
4. Wallace AM, McMahon AD, Packard CJ, *et al.* Plasma leptin and the risk of cardiovascular disease in the West of Scotland Coronary Prevention Study (WOSCOPS). *Circulation* 2001; 104: 3052-6.
5. van den Hoogen PC, Feskens EJ, Nagelkerke NJ, Menotti A, Nissinen A, Kromhout D. The relation between blood pressure and mortality due to coronary heart disease among men in different parts of the world. seven Countries Study Research Group. *N Eng J Med* 2000; 342: 1-8.

6. Sharret AR, Ballantyne CM, Coady SA, *et al.* Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-1 and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. *Circulation* 2001; 104: 1108-13.
7. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events. A meta-regression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. *Diabetes Care* 1999; 22: 233-40.
8. Ridker PM, Wilson PW, Grundy SM. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? *Circulation* 2004; 109: 2818-25. (Review)
9. Oda E, Hatada K, Katoh K, Kodama M, Nakamura Y, Aizawa Y. A case-control pilot study on n-3 polyunsaturated fatty acid as a negative risk factor for myocardial infarction. *Int Heart J.* (in press)
10. Kris-Etherton PM, Hecker KD, Binkoski AE. Polyunsaturated fatty acids and cardiovascular health. *Nutr Rev* 2004; 62: 414-26. (Review)
11. Bemelmans WJ, Broer J, Feskens EJ, *et al.* Effect of an increased intake of  $\alpha$ -linolenic acid and group nutritional education on cardiovascular risk factors: the Mediterranean Alpha-linolenic Enriched Groningen Dietary Intervention (MARGARIN) study. *Am J Clin Nutr* 2002; 75: 221-7.
12. Djousse L, Hunt SC, Arnett DK, Province MA, Eckfeldt JH, Ellison RC. Dietary linolenic acid is inversely associated with plasma triacylglycerol: the National Heart, Lung, and Blood Institute Family Heart Study. *Am J Clin Nutr* 2003; 78: 1098-102.
13. Zhao G, Etherton TD, Martin KR, West SG, Gillies PJ, Kris-Etherton PM. Dietary alpha-linolenic acid reduces inflammatory and lipid cardiovascular risk factors in hypercholesterolemic men and women. *J Nutr* 2004; 134: 2991-7.
14. Ma J, Folsom AR, Shahar E, Eckfeldt JH. Plasma fatty acid composition as an indicator of habitual dietary fat intake in middle-aged adults. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. *Am J Clin Nutr* 1995; 62: 564-71.
15. Wang L, Folsom AR, Eckfeldt JH. Plasma fatty acid composition and incidence of coronary heart disease in middle aged adults: the Atherosclerosis Risk in Communities (ARIC) Study. *Nutr Metab Cardiovasc Dis* 2003; 13: 256-66.
16. Forman BM, Chen J, Evans RM. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors  $\alpha$  and  $\delta$ . *Proc Natl Acad Sci USA* 1997; 94: 4312-7.
17. Kliewer SA, Sundseth SS, Jones SA, *et al.* Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors  $\alpha$  and  $\gamma$ . *Proc Natl Acad Sci USA* 1997; 94: 4318-23.
18. Kris-Etherton PM, Harris WS, Appel LJ. American Heart Association. Nutrition Committee. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. *Circulation* 2002; 106: 2747-57.
19. Leaf A, Kang JX, Xiao Y, Billman GE. Clinical prevention of sudden cardiac death by n-3 polyunsaturated fatty acids and mechanism of prevention of arrhythmias by n-3 fish oils. *Circulation* 2003; 107: 2646-52.
20. Thies F, Garry JM, Yaqoob P, *et al.* Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomized controlled trial. *Lancet* 2003; 361: 477-85.
21. Pepe S, McLennan PL. Cardiac membrane fatty acid composition modulates myocardial oxygen consumption and postischemic recovery of contractile function. *Circulation* 2002; 105: 2303-8.
22. Simopoulos AP. Essential fatty acids in health and chronic disease. *Am J Clin Nutr* 1999; 70 (3 Suppl): 560S-9. (Review)
23. Mori TA, Beilin LJ, Burke V, Morris J, Ritchie J. Interactions between dietary fat, fish and fish oils and their effects on platelet function in men at risk of cardiovascular disease. *Arterioscler Thromb Vasc Biol* 1997; 17: 279-86.
24. Omura M, Kobayashi S, Mizukami Y, *et al.* Eicosapentaenoic acid (EPA) induces  $Ca^{2+}$ -independent activation and translocation of endothelial nitric oxide synthase and endothelium-dependent vasorelaxation. *FEBS Lett* 2001; 487: 361-6.
25. Nakao F, Kobayashi S, Mogami K, *et al.* Involvement of Src family protein tyrosine kinases in  $Ca^{2+}$  sensitization of coronary artery contraction mediated by a sphingosylphosphorylcholine-Rho-kinase pathway. *Circ Res* 2002; 91: 953-60.
26. Wijendran V, Hayes KC. Dietary n-6 and n-3 fatty acid balance and cardiovascular health. *Annu Rev Nutr* 2004; 24: 597-615. (Review)

27. Brady LM, Lovegrove SS, Lesauvage SV, *et al.* Increased n-6 polyunsaturated fatty acids do not attenuate the effects of long-chain n-3 polyunsaturated fatty acids on insulin sensitivity or triacylglycerol reduction in Indian Asians. *Am J Clin Nutr* 2004; 79: 983-91.
28. Mozaffarian D, Ascherio A, Hu FB, *et al.* Interplay between different polyunsaturated fatty acids and risk of coronary heart disease in men. *Circulation* 2005; 111: 157-64.
29. Albert CM, Campos H, Stampfer MJ, *et al.* Blood levels of long-chain n-3 fatty acids and the risk of sudden death. *N Engl J Med* 2002; 346: 1113-8.
30. Marchioli R, Barzi F, Bomba E, *et al.* Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. *Circulation* 2002; 105: 1897-903.
31. Guallar E, Hennekens CH, Sacks FM, Willett WC, Stampfer MJ. A prospective study of plasma fish oil levels and incidence of myocardial infarction in U.S. male physicians. *J Am Coll Cardiol* 1995; 25: 387-94.
32. Bucher HC, Hengstler P, Schindler C, Meier G. N-3 polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized controlled trials. *Am J Med* 2002; 112: 298-304.
33. Tavani A, Pelucchi C, Negri E, Bertuzzi M, La Vecchia C. N-3 Polyunsaturated fatty acids, fish, and nonfatal acute myocardial infarction. *Circulation* 2001; 104: 2269-72.
34. Siscovick DS, Lemaitre RN, Mozaffarian D. The fish story: a diet-heart hypothesis with clinical implications: n-3 polyunsaturated fatty acids, myocardial vulnerability, and sudden death. *Circulation* 2003; 107: 2632-4.
35. Bang HO, Dyerberg J, Sinclair HM. The composition of the Eskimo food in north western Greenland. *Am J Clin Nutr* 1980; 33: 2657-61.
36. Sargent JR, Coupland K, Wilson R. Nervonic acid and demylinating disease. *Med Hypotheses* 1994; 42: 237-42.
37. Sandhir R, Khan M, Chahal A, Singh L. Localization of nervonic acid beta-oxidation in human and rodent peroxisomes: impaired oxidation in Zellweger syndrome and X-linked adrenoleukodystrophy. *J Lipid Res* 1998; 39: 2161-71.
38. Lecerf J. Evidence of accumulation of ceramides containing [14C] nervonic acid in the rat lung following injection of [14C] erucic acid. *Biochim Biophys Acta* 1980; 617: 398-409.
39. Dyerberg J, Bang HO, Hjorne N. Fatty acid composition of the plasma lipids in Greenland Eskimos. *Am J Clin Nutr* 1975; 28: 958-66.
40. Beare-Rogers JL. Docosenoic acids in dietary fats. *Prog Chem Fats Other Lipids* 1977; 15: 29-56. (Review)
41. Bremer J, Norum R. Metabolism of very long-chain monounsaturated fatty acids (22:1) and the adaptation to their presence in the diet. *J Lipid Res* 1982; 23: 243-56. (Review)
42. Ackman RG, Eaton CA, Dyerberg J. Marine docosenoic acid isomer distribution in the plasma of Greenland Eskimos. *Am J Clin Nutr* 1980; 33: 1814-7.